Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Sangamo Therapeutics	Krystal Biotech	Kymera Therapeutics	Immunovant	Alector
Symbol	NASDAQ:SGMO	NASDAQ:KRYS	NASDAQ:KYMR	NASDAQ:IMVT	NASDAQ:ALEC
Price Information
Current Price	$10.39	$71.86	$41.24	$16.40	$15.71
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.3	1.5	1.1	1.6	1.3
Analysis Score	3.4	3.5	2.4	3.5	3.5
Community Score	2.5	2.5	1.7	3.7	2.4
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	1.7	0.8	0.8	0.8
Earnings & Valuation Score	0.0	0.0	0.6	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$20.50	$101.00	$48.67	$45.60	$34.40
% Upside from Price Target	97.31% upside	40.55% upside	18.01% upside	178.05% upside	118.97% upside
Trade Information
Market Cap	$1.63 billion	$1.60 billion	$1.87 billion	$1.59 billion	$1.25 billion
Beta	1.97	1.2	N/A	N/A	1.08
Average Volume	1,424,825	140,556	327,400	1,314,898	624,187
Sales & Book Value
Annual Revenue	$102.43 million	N/A	N/A	N/A	$21.22 million
Price / Sales	14.58	N/A	N/A	N/A	59.05
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$3.73 per share	$11.72 per share	N/A	$1.45 per share	$2.83 per share
Price / Book	2.79	N/A	N/A	N/A	5.55
Profitability
Net Income	$-95,190,000.00	$-19,090,000.00	N/A	$-66,390,000.00	$-105,390,000.00
EPS	($0.85)	($1.20)	N/A	($1.54)	($1.71)
Trailing P/E Ratio	N/A	N/A	0.00	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-51.51%	N/A	N/A	N/A	-757.78%
Return on Equity (ROE)	-16.32%	-10.72%	N/A	-34.80%	-53.86%
Return on Assets (ROA)	-9.85%	-10.40%	N/A	-32.38%	-31.44%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	N/A	N/A
Current Ratio	5.67%	39.96%	N/A	35.15%	6.61%
Quick Ratio	5.67%	39.96%	N/A	35.15%	6.61%
Ownership Information
Institutional Ownership Percentage	57.69%	73.05%	37.83%	40.21%	61.50%
Insider Ownership Percentage	1.80%	27.40%	N/A	0.24%	13.90%
Miscellaneous
Employees	413	75	75	42	171
Shares Outstanding	143.71 million	22.20 million	45.07 million	97.97 million	79.76 million
Next Earnings Date	8/4/2021 (Estimated)	N/A	6/10/2021 (Estimated)	7/5/2021 (Estimated)	5/12/2021 (Estimated)
Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance finance.yahoo.com - May 5 at 1:50 PM
	Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans finance.yahoo.com - May 5 at 1:50 PM
	Alector (NASDAQ:ALEC) Shares Down 5.3% americanbankingnews.com - May 5 at 1:15 PM
	Alector, Inc. (NASDAQ:ALEC)’s 3.94% Gain This Week Just Tells Us Something New marketingsentinel.com - May 1 at 2:20 PM
	Alector (NASDAQ:ALEC) Downgraded by Zacks Investment Research marketbeat.com - April 28 at 4:19 PM
	Alzheimer's Disease Diagnostic Market In-Depth Analysis Of Competitive Landscape Executive Summary Development Factors 2028 – Valley Bugler Newspaper - Valley Bugler Newspaper valleybugler.com - April 28 at 8:53 AM
	Global Online Medical Market To Accelerate Growth Point to Healthy Revenue Trajectory in Coming Year 2020-2026 – By Global Marketers - Clark County Blog clarkcountyblog.com - April 28 at 3:52 AM
	Alzheimer's Disease Diagnostic Market 2021 Analysis By Regional, Outlook, Competitive Landscape Str - PharmiWeb.com pharmiweb.com - April 27 at 12:19 PM
	Morgan Stanley Raises Alector (NASDAQ:ALEC) Price Target to $33.00 americanbankingnews.com - April 26 at 9:32 AM
	Alector (NASDAQ:ALEC) Price Target Increased to $33.00 by Analysts at Morgan Stanley americanbankingnews.com - April 26 at 9:32 AM
	Alzheimer's Disease Drugs and Diagnostics Market Production, Revenue and Price Forecast by Type 2021 to 2027 – GE Healthcare, TauRx, Eisai Co. Ltd, Biogen Inc., Neuro-Bio Ltd, Cognition Therapeutics Inc., Eli Lilly and Company, Novartis AG, Accera, Alector LLC, Treventis Corporation - Clark County Blog clarkcountyblog.com - April 26 at 7:46 AM
	Alzheimer's Disease Drugs and Diagnostics Market Production, Revenue and Price Forecast by Type 2021 to 2027 – GE Healthcare, TauRx, Eisai Co. Ltd, Biogen Inc., Neuro-Bio Ltd, Cognition Therapeutics Inc., Eli Lilly and Company, Novartis AG, Accera, Alector LLC, Treventis Corporation - Clark County Blog clarkcountyblog.com - April 26 at 7:46 AM
	Neurodegenerative Diseases Industry Market to Eyewitness Massive Growth by 2028: Biogen Idec, Alector, Bayer. – Clark County Blog - Clark County Blog clarkcountyblog.com - April 24 at 8:00 AM
	Alector (NASDAQ:ALEC) Trading Down 3.3% americanbankingnews.com - April 21 at 2:02 PM
	Frontotemporal Dementia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight \| TauRx Therapeutics, Alector, Neurimmune, Biogen and Others. - Virtual-Strategy Magazine virtual-strategy.com - April 19 at 10:22 PM
	Alector (NASDAQ:ALEC) PT Raised to $33.00 americanbankingnews.com - April 19 at 10:28 AM
	2021 Latest Report on: Alzheimer S Disease Diagnostic Market Size, Demand Status \| Global Industry Segment Analysis, Growing Status of Key Players\| Eli Lilly, TauRx, Alector, Accera - Los Hijos de la Malinche loshijosdelamalinche.com - April 17 at 7:39 AM
	Alector (NASDAQ:ALEC) Trading 6.5% Higher americanbankingnews.com - April 15 at 12:50 PM
	Is Alector Inc (ALEC) a Stock to Watch After Losing -14.60% This Week? - InvestorsObserver investorsobserver.com - April 9 at 5:47 PM
	Stocks Mixed at Midday, Still on Track for Solid Weekly Gains - Schaeffers Research schaeffersresearch.com - April 9 at 12:47 PM
	Numenor Capital Portfolio Update #1 - Seeking Alpha seekingalpha.com - April 6 at 2:32 PM
	Do Analysts Expect Alector Inc (ALEC) Stock to Rise After It Has Risen 13.77% in a Month? - InvestorsObserver investorsobserver.com - March 31 at 7:48 PM
	Replay: Investing in Alzheimer’s Treatment — Jupiter Orphan Therapeutics CEO Joins Fireside Chat finance.yahoo.com - March 30 at 1:32 PM
	Check this Alector, Inc. (NASDAQ:ALEC) Analysis Before You Invest stocksregister.com - March 27 at 9:49 AM
	Alector to Present at Stifel’s 3rd Annual CNS Day - Yahoo Finance finance.yahoo.com - March 26 at 6:47 PM
	Alector to Present at Stifel's 3rd Annual CNS Day - GlobeNewswire globenewswire.com - March 25 at 10:44 PM

Date	Company	Brokerage	Action
5/3/2021	Sangamo Therapeutics	Royal Bank of Canada	Initiated Coverage
3/3/2021	Sangamo Therapeutics	Wells Fargo & Company	Lower Price Target
1/5/2021	Sangamo Therapeutics	Stifel Nicolaus	Initiated Coverage
12/16/2020	Sangamo Therapeutics	HC Wainwright	Reiterated Rating
9/8/2020	Sangamo Therapeutics	Bank of America	Initiated Coverage
7/7/2020	Sangamo Therapeutics	SunTrust Banks	Initiated Coverage
6/19/2020	Sangamo Therapeutics	Wedbush	Reiterated Rating
12/9/2019	Sangamo Therapeutics	Cowen	Reiterated Rating
11/14/2018	Sangamo Therapeutics	JPMorgan Chase & Co.	Downgrade
11/9/2018	Sangamo Therapeutics	Guggenheim	Downgrade
2/9/2021	Krystal Biotech	Jonestrading	Initiated Coverage
11/11/2020	Krystal Biotech	B. Riley	Reiterated Rating
8/25/2020	Krystal Biotech	Chardan Capital	Reiterated Rating
6/4/2020	Krystal Biotech	Evercore ISI	Initiated Coverage
5/4/2020	Krystal Biotech	William Blair	Reiterated Rating
9/24/2019	Krystal Biotech	The Goldman Sachs Group	Initiated Coverage
4/20/2021	Kymera Therapeutics	Berenberg Bank	Initiated Coverage
3/29/2021	Kymera Therapeutics	Morgan Stanley	Lower Price Target
11/13/2020	Kymera Therapeutics	Piper Sandler	Initiated Coverage
2/3/2021	Immunovant	Raymond James	Lower Price Target
2/3/2021	Immunovant	SVB Leerink	Lower Price Target
2/2/2021	Immunovant	Credit Suisse Group	Downgrade
11/13/2020	Immunovant	Truist	Boost Price Target
11/13/2020	Immunovant	Robert W. Baird	Boost Price Target
10/28/2020	Immunovant	UBS Group	Initiated Coverage
10/6/2020	Immunovant	Lifesci Capital	Reiterated Rating
10/2/2020	Immunovant	CSFB	Initiated Coverage
11/11/2020	Alector	Smith Barney Citigroup	Lower Price Target
7/29/2020	Alector	Barclays	Lower Price Target
3/5/2020	Alector	Citigroup	Initiated Coverage
11/27/2019	Alector	BTIG Research	Initiated Coverage

(Data available from 5/5/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources